Astec LifeSciences Limited, a subsidiary of Godrej Agrovet, has completed a rights issue of equity shares aggregating to approximately ₹2,382 million (₹238.2 crore). The equity shares commenced trading on the BSE and NSE on July 31, 2025.
This capital raise supports Astec’s strategy of expanding its footprint in the agrochemical sector and strengthening its R&D and manufacturing capabilities.
Also Read: Amagi Media Labs Files for ₹1,020 Crore IPO — CAM and Trilegal Advise
| Feature | Details |
|---|---|
| Issuer | Astec LifeSciences Limited |
| Parent Company | Godrej Agrovet Limited |
| Transaction Type | Rights Issue of Equity Shares |
| Deal Size | ₹2,382 million (approx.) |
| Listing Date | July 31, 2025 |
| Stock Exchanges | BSE and NSE |
| Use of Proceeds | Working capital, capex, and general corporate purposes |
Legal Advisory
Cyril Amarchand Mangaldas – Legal Counsel to Astec LifeSciences
CAM advised on all legal and regulatory aspects of the rights issue, including structuring, drafting, and documentation, as well as liaising with regulatory authorities and managing the listing process.
The transaction was led by:
Yash Ashar, Senior Partner
Devaki Mankad, Partner, Regional Co-Head – Capital Markets – West
Abhyuday Bhotika, Partner
They were supported by:
Veena Raghav, Senior Associate Designate
Anna Kallivayalil, Associate
Mahima Aggarwal, Associate
Strategic Significance
This rights issue strengthens Astec’s capital structure and allows the company to invest in its future growth. With a focus on backward integration and innovation, the company is well-positioned to cater to rising demand for high-quality agrochemical solutions in India and abroad.
The transaction also underscores the continued investor confidence in the Godrej Group’s long-term strategy in the agribusiness and specialty chemicals sectors.
Why It Matters
This deal reflects the growing use of rights issues as a capital-raising tool in India’s capital markets, especially for companies aiming to maintain promoter holding while tapping into market appetite.
For more legal deal updates and analysis, stay tuned to TheCourtroom.in
Disclaimer
This article is for informational purposes only and does not constitute legal or financial advice. Readers should consult professionals before making decisions.
